# Rejuveron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rejuveron

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.rejuveron.com
- Latest round: Series B (Sep 11, 2023)
- Investors on record: 3

## About

Based in Switzerland, and founded in 2019, Rejuveron Life Sciences AG is a clinical-stage biotechnology company providing aging therapies. The company was co-founded by Christian Angermayer, Matthias Steger, Prof. Manuel Serrano, and Timothy Cash. As of 2023, the company is headed by its CEO Aksana Labokha. In September 2023, the firm raised an amount of venture debt funding from investors. The round was part of a larger USD 75 million in Series B and debt funding.

The company offers novel therapies to tackle diseases of aging. It helps people to age better and live longer. The firm operates its state-of-the-art laboratory facilities in the Schlieren Bio-Technopark.

The company plans to use the September 2023 funding to support healthy aging and accelerate its presence in the Middle East.

## Funding rounds

- Series B, Sep 11, 2023 — Apeiron Investment Group, Mubadala Capital, Catalio Capital Management

## Investors

- Apeiron Investment Group (https://capitalatlas.ai/funds/apeiron-investment-group) — Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B